(NASDAQ: ANAB) Anaptysbio's forecast annual revenue growth rate of 0.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Anaptysbio's revenue in 2025 is $123,164,000.On average, 7 Wall Street analysts forecast ANAB's revenue for 2025 to be $3,831,944,326, with the lowest ANAB revenue forecast at $1,400,688,059, and the highest ANAB revenue forecast at $7,167,222,528. On average, 7 Wall Street analysts forecast ANAB's revenue for 2026 to be $3,231,549,454, with the lowest ANAB revenue forecast at $1,119,878,520, and the highest ANAB revenue forecast at $6,520,492,683.
In 2027, ANAB is forecast to generate $3,827,604,797 in revenue, with the lowest revenue forecast at $2,493,129,555 and the highest revenue forecast at $5,162,639,977.